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An increasing body of evidence suggests that
genetic factors modify the toxicokinetics of
lead. The gene for the δ -aminolevulinic acid
dehydratase (ALAD) enzyme has been a
focus of primary interest. Human ALAD is
encoded by a single gene on chromosome
9p34 that has two alleles, ALAD1 and
ALAD2, resulting in three isozymes, ALAD1-
1, ALAD1-2, and ALAD2-2 (1,2). The
prevalence of the ALAD2 allele is approxi-
mately 10% in Asians and 20% in Caucasians
(3–5). Subjects who have at least one copy of
the ALAD2 allele, compared to subjects with
none, have higher blood lead levels (3–5);
lower dimercaptosuccinic acid (DMSA)-
chelatable lead levels (6); lower plasma
aminolevulinic acid levels (7); a larger differ-
ence between trabecular and cortical bone
lead levels (8); higher blood urea nitrogen and
serum creatinine levels (8); less efficient
uptake of lead into bone, especially trabecular
bone (9); lower zinc protoporphyrin (ZPP)
levels for given levels of blood lead (10); and
lower urinary calcium and creatinine levels
(11). ALAD has been identiﬁed as a principal
lead-binding protein, and the proportion of
lead bound to ALAD was greater for subjects
with ALAD2 (12).
Recent data suggest that polymorphisms
in the vitamin D receptor (VDR) gene inﬂu-
ence tibia lead levels (13). The VDR gene is
located at chromosome 12cen-12 (14), and
thus variant VDR alleles would not be
expected to be linked with variant ALAD
alleles. Most studies of the VDR gene have
focused on the BsmI polymorphism; restric-
tion enzyme digestion produces three geno-
types commonly termed bb, Bb, and BB.
The BB allele (deﬁned by the absence of the
polymorphic restriction site) has a prevalence
of 7–32% in Caucasians (15). Study subjects
(mainly women) with the BB genotype have
bone mineral densities up to 10–15% lower
than subjects with the bb genotype, with an
overall difference across studies of 2–2.5%
reported in a recent meta-analysis (15). As
lead and calcium are known to behave simi-
larly in biologic systems, these ﬁndings have
motivated investigations of VDR genotype
and bone lead levels. Subjects with the B
allele had larger tibia lead concentrations
with increasing age and lower tibia lead con-
centrations with increasing duration since last
exposure to lead than did subjects without
the B allele (13).
No prior studies have evaluated the joint
inﬂuence of the VDR and ALAD genes on
bone, blood, and chelatable lead levels. Here
we report the largest such study to date in a
cross-sectional analysis of 798 Korean lead
workers and 135 controls without occupa-
tional lead exposure. 
Materials and Methods
Study overview and design. The results pre-
sented here are a cross-sectional analysis of
data from the ﬁrst year of a 3-year longitudi-
nal study of the health effects of occupational
inorganic lead exposure (16). Enrollment
began in October 1997 with the ﬁrst of three
annual evaluations for each study subject. The
current report is focused on the inﬂuence of
the ALAD and VDR polymorphisms on
blood lead, tibia lead, and dimercaptosuccinic
acid (DMSA)-chelatable lead levels measured
during this ﬁrst study evaluation and is based
on the 798 lead workers and 135 controls
without occupational lead exposure who were
enrolled between 24 October 1997 and 19
August 1999. The study was reviewed and
approved by institutional review boards at the
Johns Hopkins School of Hygiene and Public
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Articles
A cross-sectional study was performed to evaluate the influence of polymorphisms in the
δ -aminolevulinic acid dehydratase (ALAD) and vitamin D receptor (VDR) genes on blood lead,
tibia lead, and dimercaptosuccinic acid (DMSA)-chelatable lead levels in 798 lead workers and
135 controls without occupational lead exposure in the Republic of Korea. Tibia lead was
assessed with a 30-min measurement by 109Cd-induced K-shell X-ray ﬂuorescence, and DMSA-
chelatable lead was estimated as 4-hr urinary lead excretion after oral administration of 10 mg/kg
DMSA. The primary goals of the analysis were to examine blood lead, tibia lead, and DMSA-
chelatable lead levels by ALAD and VDR genotypes, controlling for covariates; and to evaluate
whether ALAD and VDR genotype modified relations among the different lead biomarkers.
There was a wide range of blood lead (4–86 µg/dL), tibia lead (–7–338 µg Pb/g bone mineral),
and DMSA-chelatable lead (4.8–2,103 µg) levels among lead workers. Among lead workers, 9.9%
(n = 79) were heterozygous for the ALAD2 allele and there were no homozygotes. For VDR,
10.7% (n = 85) had the Bb genotype, and 0.5% (n = 4) had the BB genotype. Although the
ALAD and VDR genes are located on different chromosomes, lead workers homozygous for the
ALAD1 allele were much less likely to have the VDR bb genotype (crude odds ratio = 0.29, 95%
exact conﬁdence interval = 0.06–0.91). In adjusted analyses, subjects with the ALAD2 allele had
higher blood lead levels (on average, 2.9 µg/dL, p = 0.07) but no difference in tibia lead levels
compared with subjects without the allele. In adjusted analyses, lead workers with the VDR B
allele had signiﬁcantly (p < 0.05) higher blood lead levels (on average, 4.2 µg/dL), chelatable lead
levels (on average, 37.3 µg), and tibia lead levels (on average, 6.4 µg/g) than did workers with the
VDR bb genotype. The current data conﬁrm past observations that the ALAD gene modiﬁes the
toxicokinetics of lead and also provides new evidence that the VDR gene does so as well. Key
words: δ -aminolevulinic acid dehydratase, bone lead, cross-sectional study, lead, polymorphisms,
vitamin D receptor, X-ray ﬂuorescence. Environ Health Perspect 108:949–954 (2000). [Online
31 August 2000]
http://ehpnet1.niehs.nih.gov/docs/2000/108p949-954schwartz/abstract.htmlHealth, Baltimore, Maryland, and the
Soonchunhyang University School of
Medicine, Chonan, Korea. 
Study population. Participation in the
study was voluntary, and all participants pro-
vided written, informed consent. Subjects
were paid approximately $30 for their partic-
ipation. Lead workers were recruited from 24
different lead-using facilities, with participa-
tion in most facilities exceeding 80% (16).
Retired workers from three facilities who had
received medical surveillance services by
Soonchunhyang University for several years
were also recruited to participate in the study.
Routine, government-mandated industrial
hygiene sampling revealed that the study
plants did not have significant amounts of
other heavy metals such as cadmium.
Controls without occupational lead exposure
were recruited from an air conditioner assem-
bly plant that did not use lead or other heavy
metals and from hourly wage employees of
Soonchunhyang University. 
Data collection. Data collection methods
have been previously reported (16). In brief,
data were collected either at the Institute of
Industrial Medicine at Soonchunhyang
University in Chonan or on the premises of
the lead-using facilities. The following data
were collected or measured on all study sub-
jects: a standardized interview for demo-
graphics, medical history, and occupational
history; a neurobehavioral test battery con-
sisting of examiner-administered tests; blood
pressure; peripheral vibration threshold and
pinch and grip strength; a 10-mL blood
specimen by venipuncture that was stored at
–70°C as whole blood, plasma, and red
blood cells; a spot urine sample; tibia lead
concentration by X-ray ﬂuorescence; and a
4-hour urine sample after oral administra-
tion of DMSA (in lead workers only). 
Laboratory methods. Hemoglobin was
assayed by the cyanmethemoglobin method
(Beckman Coulter, Inc., Model Ac-T 8,
Fullerton, CA), and hematocrit was mea-
sured by the capillary centrifugation method
(17). Zinc protoporphyrin levels were mea-
sured with a portable hematofluorimeter
(18). Urinary creatinine was measured using
a Sigma kit (St. Louis, MO) (19). Blood lead
levels were measured with a Zeeman back-
ground-corrected atomic absorption spec-
trophotometer (Hitachi Z-8100 model;
Hitachi, Ltd., Tokyo, Japan) with the stan-
dard addition method of the National
Institute of Occupational Safety and Health
(20) at Soonchunhyang University Institute
of Industrial Medicine, a certiﬁed reference
laboratory for lead in Korea. Tibia lead was
assessed, in units of micrograms lead per
gram bone mineral, with a 30 min measure-
ment at the left mid-tibial shaft using 109Cd-
induced K-shell X-ray ﬂuorescence (XRF), as
previously described (21–23). XRF can pro-
vide negative point estimates of bone lead
concentrations; however, all point estimates
were retained in the statistical analyses,
including negative values, because this
method minimizes bias and does not require
censoring of data (24). 
We used 4-hour urinary lead excretion
after oral administration of 10 mg/kg DMSA
to measure DMSA-chelatable lead (25). Urine
lead levels were measured in the laboratories of
the Wadsworth Center at the New York State
Department of Health, Albany, New York.
Urinary lead concentrations were determined
by electrothermal atomization atomic absorp-
tion spectrometry (Perkin-Elmer Model
4100ZL, Norwalk, CT) using previously pub-
lished methods (26). Urinary lead excretion
was highly correlated with lead excretion
adjusted for differences, generally small, in
urine collection times (Pearson’s r = 0.98), so
only the unadjusted data are presented.
ALAD and VDR genotyping. We com-
pleted ALAD and VDR genotyping on 798
and 795 subjects, respectively. VDR geno-
typing was completed using previously pub-
lished methods (13). In brief, genomic DNA
was extracted from whole blood by using the
QIAamp Blood Kit (QIAGEN, Hilden,
Germany), and the BsmI polymorphic site in
intron 8 was ampliﬁed by polymerase chain
reaction (PCR) using the primers originating
in exon 7 (primer 1: 5´-CAACCAAGAC-
TACAAGTACC-GCGTCAGTGA-3´) and
intron 8 (primer 2: 5´-AACCAGCGGGAA-
GAGGTCAAGGG-3´). Subjects homozy-
gous for the presence of the BsmI restriction
site are designated bb, heterozygotes are des-
ignated Bb, and those homozygous for the
absence of the site are designated BB.
A modiﬁed PCR-based protocol was used
for ALAD genotyping and has been previous-
ly described (3–5). In brief, the initial ampli-
fication, using 3´ and 5´ oligonucleotide
primers (5´- AGACAGACATTAGCTC-
AGTA-3´) and (5´-GGCAAAGAACACG-
TCCATTC-3´), generates a 916 base pair
fragment. A second round of ampliﬁcation




and generates an 887 base pair fragment. The
ampliﬁed fragment was cleaved at the diag-
nostic Msp1 site, only present in the ALAD2
allele, and three isozymes are observed, desig-
nated ALAD1-1, ALAD1-2, and ALAD2-2. 
Statistical analysis. The primary goals of
the analysis were to examine blood lead, tibia
lead, and DMSA-chelatable lead levels by
ALAD and VDR genotypes, controlling for
covariates; and to evaluate whether ALAD
and VDR genotype modified relations
among the different lead biomarkers.
Associations between ALAD and VDR geno-
type were evaluated in contingency tables
using odds ratios (ORs) and 95% exact con-
fidence intervals (CIs) calculated with Epi
Info version 6.04b (Centers for Disease
Control and Prevention, Atlanta, GA). 
We used linear regression to separately
model blood lead, tibia lead, and DMSA-
chelatable lead levels, controlling for con-
founding variables, using statistical software
programs of SAS Institute, Inc. (Cary, NC).
In these regression models, only lead workers,
not controls, were included. Covariates exam-
ined in linear regression models included age,
sex, creatinine clearance (4-hr), hemoglobin,
hematocrit, weight, height, body mass index,
job duration, and tobacco and alcohol con-
sumption (never, previous, and current use
for each). Covariates were retained in the ﬁnal
regression models if they were either a signiﬁ-
cant predictor of blood lead, tibia lead, or
DMSA-chelatable lead levels, or if they were a
confounder of the relations between predictor
variables and the lead biomarkers. The deci-
sions regarding the variables in the final
regression models were also made to be con-
sistent with prior analyses of the data on the
subjects presented here (23). Blood lead was
modeled with and without adjustment for
hematocrit; as this adjustment did not inﬂu-
ence regression results, only unadjusted model
results are presented. 
DMSA-chelatable lead and tibia lead
were log-transformed before regressing on
covariates because of departures from nor-
mality. To estimate the mean adjusted differ-
ences between genotypes in the original scale
of each lead measure, we exponentiated the
predicted value from the regression, separate-
ly for each genotype, at the mean value of all
continuous covariates and the reference value
of all dichotomous covariates. To evaluate
nonlinear relations, quadratic terms for con-
tinuous variables (i.e., age, job duration,
weight, height) were evaluated. We evaluated
effect modiﬁcation by genotype by including
cross-product terms between the genetic vari-
ables and relevant predictor variables (i.e.,
age, sex, tibia lead, creatinine clearance). 
Results
Demographics and dose measures. Compared
to controls without occupational lead expo-
sure, lead-exposed subjects were older (40.5
vs. 34.5 years), had lower education levels
(49.9% vs. 19.2% did not complete high
school), and a lower proportion were male
(79.4% vs. 91.9%; Table 1). The majority of
both nonexposed and exposed subjects were
current users of tobacco and alcohol prod-
ucts. There was a wide range of blood
lead (4–86 µg/dL), tibia lead (–7–338 µg/g),
and DMSA-chelatable lead (4.8–2,103 µg)
levels among lead workers (Table 1). The
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control subjects were low. Among lead work-
ers, tibia lead was moderately correlated with
blood lead (Pearson’s r = 0.42), DMSA-
chelatable lead (r = 0.43), and job duration (r
= 0.40) (all p-values < 0.01). The correlations
of blood lead (r = 0.13) and DMSA-chelat-
able lead (r = 0.17) with job duration were
much lower than were the correlations of
these variables with tibia lead. Blood lead was
highly correlated with DMSA-chelatable lead
(r = 0.82). 
Prevalence and associations of genotypes.
Among lead workers, 9.9% (n = 79) were
heterozygous for the ALAD2 allele, and there
were no ALAD2 homozygotes; 11.2% (n =
89) had at least one copy of the VDR B
allele, and 0.5% (n = 4) had the BB geno-
type. The corresponding values for controls
were 8.1% (n = 11) for the ALAD2 allele and
8.9% (n = 12) and 0.7% (n = 1) for one and
two copies of the VDR B allele, respectively.
Because of the small number of subjects with
the BB genotype, all subsequent analysis
combined homozygous and heterozygous
variant allele carriers.
In unadjusted (crude) analyses, there were
no differences in age, job duration, hemoglo-
bin, blood lead, tibia lead, or DMSA-chelat-
able lead by ALAD genotype (Table 2). In
contrast, lead workers with the Bb or BB
genotypes, compared to those with bb, were
older and had higher DMSA-chelatable lead
levels (both p-values < 0.05, Table 2). 
The ALAD gene is located on chromo-
some 9, and the VDR gene is on chromosome
12. Nonetheless, an association was observed
between the ALAD and VDR genotypes
(Table 3). Among lead workers, subjects
homozygous for the ALAD1 allele were much
less likely to have the VDR bb genotype
(crude OR = 0.28; 95% CI, 0.06–0.89). In
contrast, among controls, subjects homozy-
gous for the ALAD1 allele were more likely to
have the VDR bb genotype (crude OR =
2.53; 95% CI, 0.23–14.84). Although there
were only two controls with ALAD1-2 and
VDR Bb or BB, in the stratiﬁed analysis, the
ORs between the two genes among lead
workers and controls were signiﬁcantly differ-
ent (test for homogeneity of stratum-speciﬁc
ORs, p = 0.04).
Predictors of blood lead levels in lead-
exposed subjects. After adjustment for age,
sex, and current tobacco use using linear
regression, lead workers with the VDR B
polymorphism had higher blood lead levels
(p < 0.01), in models with or without con-
trol for ALAD genotype (model with ALAD
genotype; Table 4). Subjects with the
ALAD2 allele also had higher blood lead lev-
els (p < 0.05) in models without and with
control for VDR genotype (model with
VDR genotype; Table 4). On average, after
controlling for the two genotypes, lead
workers with the VDR B polymorphism had
blood lead levels 4.2 µg/dL higher than sub-
jects with bb, and lead workers with the
ALAD2 allele had blood lead levels 3.6
µg/dL higher than subjects without the
allele. There was no evidence of gene–gene
interaction in these models (evaluated by
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Table 1. Description of study subjects, October 1997 to August 1999, Republic of Korea.
Lead-exposed
Characteristic subjects (n = 798) Controls (n = 135) 
Age (years) 40.5 ± 10.1 (17.8–64.8) 34.5 ± 9.1 (22.0–60.2)
Lead work job duration (years) 8.2 ± 6.5 (0.1–36.2) NAa
Height (cm) 164.7 ± 8.1 (127.8–186.0) 167.9 ± 6.2 (148.0–183.4)
Weight (kg) 62.5 ± 9.1 (37.4–92.7) 66.9 ± 9.0 (48.0–93.5)
Body mass index (kg/cm2) 23.0 ± 3.0  (15.7–34.2) 23.7 ± 2.8 (18.5–30.1)
Blood lead (µg/dL) 32.0 ± 15.0 (4–86) 5.3 ± 1.8 (2–10)
Tibia lead, (µg Pb/g bone mineral) 37.2 ± 40.4 (–7–338) 5.8 ± 7.0 (–11–27)
DMSA-chelatable lead (µg)b 186.0 ± 208.4( 4.8–2,103) NAa
Hemoglobin (g/dL) 14.2 ± 1.4  (6.5–17.9) 15.3 ± 1.2 (11.1–18.2)
Creatinine clearance, 4-hr (mL/min) 114.3 ± 33.9 (11.2–351.6) NAa
Educational levelc
Lower school (≤ 6 years) 183 (23.0) 10 (7.4)
Some middle school (7–8 years) 29 (3.6) 3 (2.2)
Middle school graduate (9 years) 155 (19.4) 12 (8.9)
Some high school (10–11 years) 31 (3.9) 1 (0.7)
High school graduate (12 years) 335 (42.0) 93 (68.9)
One or two years college (13–14 years) 37 (4.6) 11 (8.1)
College graduate or more 27 (3.3) 5 (3.7)
Missing 1 (< 0.1) 0 (0.0)
Sex, malec 634 (79.4) 124 (91.9)
Tobacco usec
Never 254 (31.9) 35 (25.9)
Current use 455 (57.1) 87 (64.4)
Past use 88 (11.0) 13 (9.6)
Alcohol usec
Never 231 (29.0) 31 (23.0)
Current use 518 (65.0) 95 (70.4)
Past use 48 (6.0) 9 (6.7)
Values shown are mean ± SD except where indicated. 
aThe 4-hr urine collection was performed only in subjects who received DMSA. bDMSA-chelatable lead (µg) was esti-
mated as 4-hr urinary lead excretion after oral administration of 10 mg/kg DMSA, in lead-exposed subjects only (784 sub-
jects completed the urine collection).cValues shown are number (%) 
Table 2. Selected demographic and lead biomarker variables (mean ± SD) by gene status in 798 lead-
exposed subjects, October 1997 to August 1999, Republic of Korea.a
ALAD genotype  VDR genotype 
Characteristic 1-1  1-2  bb  Bb or BB
Number 716 79 709 89
Age (years) 40.5 ± 10.2 40.1 ± 9.7 40.2 ± 10.0* 42.7 ± 10.3*
Job duration (years) 8.2 ± 6.6 8.2 ± 5.8 8.4 ± 6.6 7.2 ± 5.6
Hemoglobin (g/dL) 14.2 ± 1.4 14.2 ± 1.6 14.2 ± 1.4 14.1 ± 1.4
Blood lead (µg/dL) 31.7 ± 14.9 34.2 ± 15.9 31.6 ± 14.8 34.8 ± 16.1
Tibia lead (µg/g) 37.5 ± 40.6 31.4 ± 29.5 37.1 ± 41.2 38.1 ± 33.5
DMSA-chelatable lead (µg) 180.3 ± 181.2 161.7 ± 143.0 173.5 ± 176.8* 217.2 ± 179.7*
aALAD and VDR genotyping were completed on 795 and 798 lead workers, respectively. *p < 0.05.
Table 3. Association of VDR genotype status by ALAD genotype status.
VDR genotype
ALAD bb, n (%)a Bb or BB, n (%)a Total  OR (95% CI)b
All study participants
1-1 743 (80.0)  96 (10.3) 839 (90.3) 0.46 (0.14–1.15)
1-2 85 (9.2) 5 (0.5) 90 (9.7)
Total 828 (89.1) 101 (10.9) 929 (100)
Lead workers
1-1 629 (79.2)  86 (10.8) 715 (90.1) 0.29 (0.06–0.91)
1-2 76 (9.6) 3 (0.4) 79 (10.0)
Total 705 (88.8) 89 (11.2) 794 (100)
Controls without occupational
lead exposure
1-1 114 (84.4)  10 (7.4) 124 (91.9) 2.53 (0.23–14.84) 
1-2 9 (6.7) 2 (1.5) 11 (8.1)
Total 123 (91.1) 12 (8.9) 135 (100)
aPercentage of table totals. bTest for homogeneity of stratum-speciﬁc ORs, p = 0.04, indicating that the association of the
two genotypes in lead workers and controls was different.inclusion of an ALAD–VDR cross-product
term). There was also no evidence of effect
odiﬁcation by ALAD or VDR genotype on
the relations of the predictor variables with
blood lead levels. The ﬁnal linear regression
model (Table 4) accounted for 35% of the
variance in blood lead levels. 
Predictors of DMSA-chelatable lead lev-
els in lead-exposed subjects. After adjustment
for covariates (age, sex, current tobacco use,
body mass index, and 4-hr creatinine clear-
ance), subjects with the VDR B polymor-
phism had higher DMSA-chelatable lead lev-
els (on average, 32%, or 37.3 µg higher than
subjects with VDR bb, p < 0.01). In contrast,
the ALAD2 allele was not signiﬁcantly associ-
ated with chelatable lead levels (p = 0.69).
The relation between creatinine clearance
and DMSA-chelatable lead was modiﬁed by
ALAD genotype (Table 5, model 3). The
intercept for lead workers with the ALAD2
allele was 59% lower than for lead workers
with the ALAD1 allele (p = 0.05). Among
lead workers with only the ALAD1 allele,
chelatable lead levels increased 5.8 µg for
each increase of 10 mL/min in creatinine
clearance near its mean value (p < 0.01); in
contrast, among lead workers with the
ALAD2 allele, chelatable lead levels increased
15.5 µg for each increase of 10 mL/min in
creatinine clearance near its mean value (dif-
ference in two slopes, p = 0.04). The ﬁnal lin-
ear regression models accounted for 25–26%
of the variance in DMSA-chelatable lead lev-
els. Addition of blood lead to the models of
DMSA-chelatable lead increased the model
r2 to 79–80%. There were no interactions in
these models between blood lead and either
of the two genes.
Predictors of tibia lead levels in lead-
exposed subjects. After adjustment for age (lin-
ear and quadratic terms), sex, job duration,
and body mass index, ALAD genotype was
not associated with tibia lead levels (Table 6,
model 1, p = 0.73), but VDR genotype was
associated (Table 6, model 2, p = 0.03). On
average, subjects with the VDR B allele had
tibia lead levels that were 29%, or 6.4 µg/g,
higher than did subjects without the allele.
The final regression models accounted for
15% of the variance in tibia lead levels.
VDR genotype reportedly influences
bone mineral density, so we examined the
inﬂuence of VDR genotype on age- and sex-
associated differences in tibia lead levels.
There were no interactions observed between
VDR genotype and age on tibia lead levels in
all lead workers or in speciﬁc subgroups (i.e.,
males, females, older subjects), and no 
interaction between VDR genotype and sex
on tibia lead levels. 
Predictors of lead biomarkers in controls
without occupational lead exposure. In linear
regression models including only controls,
none of these genetic associations with blood
lead, DMSA-chelatable lead, or tibia lead
levels were observed. 
Discussion
The current study confirms past observa-
tions that the ALAD gene modifies the
toxicokinetics of lead and also provides new
evidence that the VDR gene does so as well.
In fact, the inﬂuence of the VDR B allele on
blood lead levels was larger than was the
inﬂuence of the ALAD2 allele. The mecha-
nism by which these genes inﬂuence blood
lead levels may differ. ALAD2 and VDR B
were associated with higher blood lead levels;
however, only VDR B was associated with
higher tibia lead levels (p = 0.03). 
In adjusted analyses, subjects with the
VDR B allele had significantly (p < 0.05)
higher blood lead levels (on average, 4.2
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Table 4. Linear regression modeling of blood lead, Korean lead workers, 1997–1999.a
Independent Units  of  ββ
variable coefﬁcient coefﬁcient β SE  p -Value
Age µg/dL/year 0.286 0.049 < 0.001
Female µg/dL –13.782 1.382 < 0.001
Current smoker µg/dL 3.406 1.081 0.002
Tibia lead µg/dL/µg/g 0.131 0.011 < 0.00
VDR, Bx vs. bb µg/dL 4.183 1.376 0.002
ALAD, 12 vs. 11 µg/dL 3.627 1.445 0.01
aModel r2 = 0.35. 
Table 5. Linear regression modeling of DMSA-chelatable lead, Korean lead workers, 1997–1999.
Independent Units  of 
variable β coefﬁcient β coefﬁcient β SE  p-Value Model r2
Model 1 0.26
Age µg/year 0.033 0.004 < 0.001
Female µg –0.958 0.105 <  0.001
Current smoker µg 0.299 0.080 < 0.001
Body mass index µg/kg/cm2 0.010 0.012 0.40
Creatinine clearance µg/mL/min 0.006 0.001 < 0.001
VDR, Bx vs. bb µg 0.282 0.103 0.006
Model 2 0.25
Age µg/year 0.034 0.004 < 0.001
Female µg –0.946 0.106 < 0.001
Current smoker µg 0.310 0.081 < 0.001
Body mass index µg/kg/cm2 0.013 0.012 0.26
Creatinine clearance µg/mL/min 0.006 0.001 < 0.001
ALAD, 12 vs. 11 µg 0.044 0.108 0.69
Model 3 0.26
Age µg/year 0.034 0.004 < 0.001
Female µg –0.937 0.106 < 0.001
Current smoker µg 0.307 0.081 < 0.001
Body mass index µg/kg/cm2 0.012 0.012 0.29
Creatinine clearance µg/mL/min 0.005 0.001 < 0.001
ALAD, 12 vs. 11 µg –0.890 0.458 0.05
ALAD × creatinine clearancea µg/mL/min 0.008 0.004 0.04
aDMSA-chelatable lead was log-transformed for these regressions because of departure from normality.
Table 6. Linear regression modeling of tibia lead, Korean lead workers, 1997–1999.a
Independent Units  of 
variable β coefﬁcient β coefﬁcient β SE  p-Value
Model 1b
Age µg/g/ year 0.014 0.005 0.002
Age2  µg/g/year2 0.001 0.0003 0.003
Female µg/g –0.407 0.104 < 0.001
Job duration µg/g/year 0.048 0.007 < 0.001
Body mass index µg/g/kg/cm2 0.033 0.013 0.01
ALAD (12 vs. 11) µg/g 0.042 0.122 0.73
Model 2b
Age µg/g/year 0.013 0.005 0.006
Age2  µg/g/year2 0.001 0.0003 0.002
Female µg/g –0.412 0.103 < 0.001
Job duration µg/g/year 0.050 0.007 < 0.001
Body mass index µg/g/kg/cm2 0.030 0.013 0.02
VDR (Bx vs. bb) µg/g 0.254 0.117 0.03
aTibia lead was log-transformed for these regressions because of departure from normality. bModel r2 = 0.15.µg/dL), chelatable lead levels (on average,
37.3 µg), and tibia lead levels (on average, 6.4
µg/g) than did subjects with the VDb geno-
type. VDR genotype did not modify relations
between such factors as age, sex, and renal
function and any of the lead dose measures.
In part, these observations may be explained
by the greater intestinal absorption of lead, or
greater uptake and subsequent release of lead
from bone, in individuals with VDR B
(13,27–32). Vitamin D, after binding to the
VDR receptor, increases intestinal absorption
of calcium and lead. The VDR B allele has
been associated with lower bone mineral den-
sities and higher tibia lead levels (13,15), but
the mechanism underlying these observations
is not currently known. Interpretation of the
observation that lead workers with the VDR
B allele have higher tibia lead levels than do
workers with VDR bb is complicated by the
fact that VDR genotype is likely to inﬂuence
the content of both calcium and lead in bone
and tibia lead concentration as measured by
XRF is standardized to bone mineral content.
Thus, higher tibia lead concentrations can be
due to higher lead content, lower calcium
content, or both.
In adjusted analyses, subjects with the
ALAD2 allele had higher blood lead levels (on
average, 3.6 µg/dL; p = 0.01) but no differ-
ences in tibia or chelatable lead levels com-
pared to subjects without the allele. Creatinine
clearance was an important predictor of
chelatable lead levels and ALAD genotpe
modiﬁed the relation between creatinine clear-
ance and chelatable lead. Subjects with the
ALAD2 allele had larger increases in chelatable
lead levels with increasing creatinine clearance
than did subjects without the allele. We previ-
ously reported that subjects with ALAD2 had
lower DMSA-chelatable lead levels than did
lead workers with ALAD1 (6). It is important
to note that in the previous study, DMSA was
administered at 5 mg/kg, and mean DMSA-
chelatable lead levels were approximately half
of those in the current study, in which workers
were administered 10 mg/kg DMSA. These
data are consistent with earlier observations
that the ALAD2 allele increases erythrocytic
binding of lead (3–12). This increase in intra-
erythrocytic lead may decrease the relative
deposition of lead in critical target organs and
thus protect against the toxicity of lead. 
An unexpected observation was that
ALAD and VDR genotypes were associated.
These genes are located on different chromo-
somes. Lead workers with the ALAD1-1
genotype were much less likely to have the
VDR bb genotype (OR = 0.29, p < 0.05).
Although this observation has to be inter-
preted with caution because only three lead
workers had the ALAD1-2 and VDR Bb or
BB genotypes, the exact conﬁdence interval
did not include 1.0. The data also suggested
that the association between the two geno-
types in the controls without occupational
lead exposure was different, in that controls
with the ALAD1-1 genotype were more like-
ly to have the VDR bb genotype (OR = 2.5),
and the stratum-specific ORs were signifi-
cantly different. This is not a stable estimate,
however, due to small cell sizes, and requires
conﬁrmation. One study reported that dif-
ferential selection in the lead industry may
occur by ALAD genotype (3), and the cur-
rent data are further evidence that genetic
factors may inﬂuence the duration of work
in the lead industry. 
To date, data would suggest that the
ALAD1 allele is more likely to confer health
risks associated with lead exposure. For the
VDR genotype, data are insufﬁcient to deter-
mine whether the polymorphisms are likely
to modify health risks due to lead and which
allele is the allele of risk. We speculate that
the alleles for either ALAD or VDR that con-
fer health risk should become less prevalent
with increasing duration of occupational
exposure to lead (3); this could occur, for
example, if the at-risk alleles are associated
with the development of acute symptoms
that increase the probability of quitting jobs
with lead exposure. We have no information
in former lead workers on either symptoms
or work duration by ALAD or VDR geno-
type, and serial blood lead measurements
from the start of employment are not avail-
able for the majority of lead workers. These
limitations weaken the inferences that we can
make at this time. However, compared to the
controls, it appears that lead workers have
higher prevalences of both the ALAD2 and
VDR B alleles (10.3% vs. 8.1% and 11.4%
vs. 8.9%, respectively). This observation
would support the inference that the ALAD2
allele is “protective,” as is the VDR B allele,
and that there may be selection by genotype
among lead workers, but this speculation
requires further study. 
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